Research programme: RNAi therapeutics - Alnylam/Ionis

Drug Profile

Research programme: RNAi therapeutics - Alnylam/Ionis

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; Isis Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Small interfering RNA
  • Mechanism of Action 5 aminolevulinate synthetase inhibitors; Antithrombin III inhibitors; Apolipoprotein A inhibitors; Factor XI inhibitors; Haemostasis stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Acute intermittent porphyria; Atherosclerosis; Haemophilia; Hyperlipoproteinaemias; Venous thromboembolism

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 15 Jan 2015 Research programme: RNAi therapeutics - Alnylam/Isis is available for licensing as of 15 Jan 2015. http://isispharm.com/ http://www.alnylam.com/
  • 09 Jan 2015 Early research in Atherosclerosis, Acute intermittent porphyria, Haemophilia, Hyperlipoproteinaemia and Venous thromboembolism in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top